ProfoundBio is a US-based biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer.
Location: China, Jiangsu, Suzhou
Employees: 51-200
Total raised: $112M
Investors 2
| Date | Name | Website |
| 15.02.2024 | Octagon Ca... | octagoninv... |
| 10.03.2023 | B Capital ... | bcapgroup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.02.2024 | Series B | $112M | - |
Mentions in press and media 15
| Date | Title | Description |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M. The round added Frazier Life Sc... |
| 13.02.2024 | ProfoundBio Raises $112M in Series B Funding | ProfoundBio, a Seattle, WA-based clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer, raised $112M in Series B funding. The round was led by Ally Bridge Group, with parti... |
| 05.10.2023 | ProfoundBio to Participate in the Bank of America 2023 Healthcare Trailblazers Private Company Conference | SEATTLE, Oct. 5, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one mee... |
| 28.09.2023 | ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023 | SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC p... |
| 28.08.2023 | ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference | SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one me... |
| 26.05.2023 | ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic | PRO1160 first patient dosed in the US China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023... |
| 24.03.2023 | ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting | WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present two posters from ... |
| 03.01.2023 | ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Lett... | PRO1184 first-in human study initiated and first patients dosed PRO1160 first-in-human study cleared for initiation in the US Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platfo... |
| 03.08.2022 | ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medi... | SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics, announced that it has received clearance from the U.S. Food... |
| 02.06.2022 | ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic | - Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more effici... |
Show more